Development of a Risk Model for Pediatric Hospital-Acquired Thrombosis: A Report from the Children's Hospital-Acquired Thrombosis Consortium.


Journal

The Journal of pediatrics
ISSN: 1097-6833
Titre abrégé: J Pediatr
Pays: United States
ID NLM: 0375410

Informations de publication

Date de publication:
01 2021
Historique:
received: 05 06 2020
revised: 02 09 2020
accepted: 04 09 2020
pubmed: 14 9 2020
medline: 3 2 2021
entrez: 13 9 2020
Statut: ppublish

Résumé

To identify pertinent clinical variables discernible on the day of hospital admission that can be used to assess risk for hospital-acquired venous thromboembolism (HA-VTE) in children. The Children's Hospital-Acquired Thrombosis Registry is a multi-institutional registry for all hospitalized participants aged 0-21 years diagnosed with a HA-VTE and non-VTE controls. A risk assessment model (RAM) for the development of HA-VTE using demographic and clinical VTE risk factors present at hospital admission was derived using weighted logistic regression and the least absolute shrinkage and selection (Lasso) procedure. The models were internally validated using 5-fold cross-validation. Discrimination and calibration were assessed using area under the receiver operating characteristic curve and Hosmer-Lemeshow goodness of fit, respectively. Clinical data from 728 cases with HA-VTE and 839 non-VTE controls, admitted between January 2012 and December 2016, were abstracted. Statistically significant RAM elements included age <1 year and 10-22 years, cancer, congenital heart disease, other high-risk conditions (inflammatory/autoimmune disease, blood-related disorder, protein-losing state, total parental nutrition dependence, thrombophilia/personal history of VTE), recent hospitalization, immobility, platelet count >350 K/μL, central venous catheter, recent surgery, steroids, and mechanical ventilation. The area under the receiver operating characteristic curve was 0.78 (95% CI 0.76-0.80). Once externally validated, this RAM will identify those who are at low-risk as well as the greatest-risk groups of hospitalized children for investigation of prophylactic strategies in future clinical trials.

Identifiants

pubmed: 32920105
pii: S0022-3476(20)31144-6
doi: 10.1016/j.jpeds.2020.09.016
pmc: PMC7752847
mid: NIHMS1629153
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

252-259.e1

Subventions

Organisme : NHLBI NIH HHS
ID : L40 HL138910
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001855
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Julie Jaffray (J)

Children's Hospital Los Angeles, Los Angeles, CA; University of Southern California Keck School of Medicine, Los Angeles, CA. Electronic address: jjaffray@chla.usc.edu.

Brian Branchford (B)

Children's Hospital Colorado, Aurora, CO; University of Colorado School of Medicine, Aurora, CO.

Neil Goldenberg (N)

Johns Hopkins All Children's Hospital, Baltimore, MD; Department of Pediatrics and Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.

Jemily Malvar (J)

Children's Hospital Los Angeles, Los Angeles, CA.

Stacy E Croteau (SE)

Boston Children's Hospital, Boston, MA; Harvard Medical School, Boston, MA.

Michael Silvey (M)

Children's Mercy Kansas City, Kansas City, MO.

John H Fargo (JH)

Akron Children's Hospital, Akron, OH.

James D Cooper (JD)

Children's Hospital of Pittsburgh, Pittsburgh, PA.

Nihal Bakeer (N)

Indiana Hemophilia and Thrombosis Center, Indianapolis, IN.

Richard Sposto (R)

University of Southern California Keck School of Medicine, Los Angeles, CA.

Lingyun Ji (L)

University of Southern California Keck School of Medicine, Los Angeles, CA.

Neil A Zakai (NA)

Department of Medicine, Department of Pathology & Laboratory Medicine, Larner College of Medicine at the University of Vermont Burlington, Burlington, VT.

E Vincent S Faustino (EVS)

Department of Pediatrics, Yale School of Medicine, New Haven, CT.

Amy Stillings (A)

Children's Hospital Los Angeles, Los Angeles, CA.

Emily Krava (E)

Children's Hospital Los Angeles, Los Angeles, CA.

Guy Young (G)

Children's Hospital Los Angeles, Los Angeles, CA; University of Southern California Keck School of Medicine, Los Angeles, CA.

Arash Mahajerin (A)

CHOC Children's Hospital, Mission Viejo, CA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH